Stocksigma LogoStocksigma Logo

Eris Lifesciences Delivers Solid Q2 FY27 Results Driven by Core DBF Franchise

Eris Lifesciences reported consolidated revenue growth of 12.6% YoY to Rs. 892 cr in Q2 FY27, with EBITDA rising 7.3% YoY to Rs

Eris Lifesciences Delivers Solid Q2 FY27 Results Driven by Core DBF Franchise

Eris Lifesciences Ltd 路 Investor Presentation 路 26 Oct 2026, 7:25 pm

Eris Lifesciences Delivers Solid Q2 FY27 Results Driven by Core DBF Franchise Eris Lifesciences reported consolidated revenue growth of 12.6% YoY to Rs. 892 cr in Q2 FY27, with EBITDA rising 7.3% YoY to Rs. 309 cr (34.7% margin) and PAT surging 39.2% YoY to Rs. 187 cr (Adjusted PAT up 17.5% to Rs. 158 cr). Domestic Branded Formulations revenue climbed 14.1% YoY to Rs. 809 cr, driven by chronic therapies. In H1 FY27, ROCE expanded to 19% from 16% in FY26, alongside a net debt reduction of ~Rs. 111 cr.

Original exchange filing (PDF)

More announcements from Eris Lifesciences Ltd

All Eris Lifesciences Ltd announcements